Gilead Builds Japan Oncology Presence With Trodelvy
Yescarta Also Back In House
Gilead aims to launch its key oncology product Trodelvy by 2024 in Japan while building a dedicated business unit for oncology in the firm’s Japanese office. The firm has expanded its exclusive rights for oncology products in APAC.
You may also be interested in...
Kite’s senior director and head of medical affairs, Intercontinental Region, Tony Li, talks to Scrip about the company's efforts to enable timely and broad access to Yescarta in Singapore, where wider cancer drug procurement prices have declined following policy changes. A patient is already on course to being prepped for Kite's CAR-T cell therapy.
Two weeks after obtaining its third cancer indication and the same day Kite CEO Christi Shaw’s departure was announced, Gilead’s antibody-drug conjugate yielded Phase II data it says will help toward full approval in urothelial cancer.
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.